|
Patent landscape, scope, and claims: |
United States Drug Patent 6,987,103: Scope, Claims, and Landscape Analysis
US Patent 6,987,103, titled "Azaindole derivatives and their use as kinase inhibitors," was granted on January 17, 2006, to Novartis AG. The patent covers a genus of azaindole derivatives and their application in treating proliferative disorders by inhibiting the activity of protein kinases. The core innovation lies in a specific chemical structure and its demonstrated pharmacological effect.
What Is the Core Chemical Structure Claimed?
The patent's primary claims define a broad structural class of azaindole compounds.
-
Claim 1, the broadest independent claim, recites a compound of Formula I:
[Image of Formula I from patent 6,987,103 would be inserted here if technically feasible]
where:
- Ar is a phenyl group or a heteroaryl group;
- R¹ is hydrogen, alkyl, haloalkyl, alkoxyalkyl, or hydroxyalkyl;
- R² is hydrogen, alkyl, haloalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acylaminoalkyl, or carbamoylalkyl;
- R³ is hydrogen, alkyl, haloalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, acylaminoalkyl, or carbamoylalkyl;
- R⁴ is hydrogen, alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, or carbamoylalkyl;
- R⁵ is hydrogen, alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, carbamoylalkyl, hydroxyl, alkoxy, amino, nitro, halo, cyano, acylamino, or carbamoyl;
- R⁶ is hydrogen, alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, or carbamoylalkyl;
- X is a linking group comprising at least one heteroatom; and
- Y is a nitrogen atom or a carbon atom.
-
Dependent claims further narrow this genus by specifying particular substituents and their positions on the azaindole ring and the Ar group. For example, claims specify the nature of the linking group X and the aromatic or heteroaromatic nature of the Ar substituent.
-
Claim 17 claims a pharmaceutical composition comprising a compound according to any one of claims 1 to 16 and a pharmaceutically acceptable carrier.
-
Claim 18 claims a method of treating a proliferative disorder in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a compound according to any one of claims 1 to 16.
What Are the Key Kinase Targets and Therapeutic Indications?
The patent explicitly identifies the inhibition of protein kinases as the mechanism of action for the claimed compounds.
-
Kinase Inhibition: The specification details the inhibitory activity of the exemplified compounds against several key kinases, including but not limited to:
- Src kinase
- EGFR (Epidermal Growth Factor Receptor)
- VEGFR (Vascular Endothelial Growth Factor Receptor)
- PDGFR (Platelet-Derived Growth Factor Receptor)
- FGFR (Fibroblast Growth Factor Receptor)
- CDKs (Cyclin-Dependent Kinases)
-
Therapeutic Indications: The primary therapeutic use described is the treatment of proliferative disorders. This encompasses conditions characterized by uncontrolled cell growth, including various forms of cancer.
- Cancer Types: The patent lists a range of cancers, such as:
- Solid tumors (e.g., breast, lung, colon, prostate, ovarian, pancreatic cancers)
- Leukemias
- Lymphomas
- Sarcomas
- Other Proliferative Disorders: The scope extends to non-cancerous proliferative conditions, although cancer is the predominant focus.
What Is the Patent's Geographic Coverage and Term?
US Patent 6,987,103 is specific to the United States.
- Jurisdiction: United States of America.
- Original Grant Date: January 17, 2006.
- Original Expiration Date: January 17, 2026.
- Patent Term Adjustment (PTA): The patent term was subject to adjustments due to delays in prosecution at the USPTO. A specific PTA calculation would determine the precise adjusted expiration date. For patents granted after May 29, 1999, the term is 20 years from the earliest effective filing date, subject to PTA.
- Regulatory Exclusivity: Beyond patent expiration, approved drugs may also benefit from market exclusivity granted by regulatory bodies like the FDA. For instance, a New Chemical Entity (NCE) designation typically provides 5 years of exclusivity in the U.S.
What Is the Prior Art Landscape at the Time of Filing?
The patent application was filed in the early 2000s, a period of intense research in kinase inhibitors for cancer therapy.
- Kinase Inhibitor Research: Significant advancements were being made in understanding the role of aberrant kinase signaling in cancer pathogenesis. This led to the development of numerous small molecule inhibitors targeting specific kinases.
- Existing Kinase Inhibitor Patents: Numerous patents existed and were being filed by major pharmaceutical companies (e.g., Pfizer, Bristol-Myers Squibb, AstraZeneca) covering various classes of kinase inhibitors, including those targeting receptor tyrosine kinases (RTKs) like EGFR and VEGFR, and intracellular kinases like Src.
- Azaindole Scaffolds: The azaindole chemical scaffold itself was not novel. It had appeared in the literature and in other patent applications for its biological activity, often in the context of kinase inhibition.
- Patentability Challenges: The key to the patentability of US 6,987,103 would have been demonstrating that the claimed azaindole derivatives provided a novel and non-obvious improvement over existing compounds, particularly in terms of potency, selectivity, pharmacokinetic properties, or therapeutic efficacy against specific kinase targets. The breadth of Formula I suggests an attempt to claim a wide chemical space around a core structure.
What Are the Key Examples and Data Presented?
The patent's specification includes numerous examples demonstrating the synthesis and biological activity of specific azaindole derivatives.
-
Synthesis: Detailed synthetic routes are provided for preparing various compounds within the claimed genus. These routes typically involve multi-step organic synthesis, highlighting the chemical complexity.
-
Biological Data:
- Kinase Inhibition Assays: The patent provides data from in vitro kinase inhibition assays, typically reporting IC50 values (the concentration of inhibitor required to reduce the activity of a target enzyme by 50%). These values demonstrate the potency of the exemplified compounds against specific kinases (e.g., Src, EGFR, PDGFR). Table data would typically present specific IC50 values for each exemplified compound against a panel of kinases.
- Cell-Based Assays: Some examples may include data from cell-based assays demonstrating the ability of the compounds to inhibit cell proliferation or induce apoptosis in cancer cell lines.
- In Vivo Studies (Limited): While less common in early-stage patents, some examples might include preliminary in vivo data in animal models of cancer, showing tumor growth inhibition.
-
Example Compounds: A detailed examination of the patent's examples would reveal specific chemical structures that fall within the broader Formula I and for which biological data is presented. These examples are crucial for understanding the practical embodiment of the invention and for any subsequent infringement analysis. For instance, specific examples might detail compounds with substitutions at R¹, R², R³, R⁴, R⁵, R⁶ and specific linking group X and Ar moieties.
What Are the Enforcement and Litigation Considerations?
US Patent 6,987,103 is a granted patent, making it a potential basis for enforcement actions against manufacturers of infringing products.
-
Infringement Analysis: Determining infringement requires comparing the structure of a competitor's drug product with the claims of US 6,987,103. This involves:
- Claim Construction: Interpreting the precise meaning and scope of each term in the patent claims. This is often a contentious process in litigation.
- Structural Comparison: Assessing whether the competitor's compound falls within the structural boundaries defined by the claims, including any specified substituents and their allowed variations.
- Doctrine of Equivalents: Even if a competitor's product does not literally infringe a claim, it may still infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result, with only insubstantial differences.
-
Validity Challenges: A patent can be challenged on grounds of invalidity. Common challenges include:
- Prior Art: Demonstrating that the claimed invention was already known or obvious from the prior art at the time of filing.
- Enablement and Written Description: Arguing that the patent specification does not adequately describe the invention or enable a person skilled in the art to make and use it.
- Obviousness-Type Double Patenting (ODP): If the patent claims subject matter that is obvious over subject matter claimed in another patent owned by the same applicant with an overlapping term.
-
Litigation History: A search of patent litigation databases is essential to determine if US 6,987,103 has been involved in any past or ongoing lawsuits. This provides insights into the patent's perceived strength, claim construction interpretations by courts, and potential validity issues.
What Is the Competitive Landscape for Azaindole Kinase Inhibitors?
The azaindole scaffold has been explored by multiple companies for kinase inhibition, creating a complex competitive environment.
-
Novartis's Pipeline: US 6,987,103 is linked to Novartis's R&D efforts. Identifying specific drug candidates developed by Novartis that fall under this patent is crucial. For example, if any of Novartis's marketed or pipeline kinase inhibitors share the core azaindole structure and are within the scope of Formula I, they would be protected by this patent.
-
Competitor Activity: Other pharmaceutical companies have also developed and patented azaindole-based kinase inhibitors. Key competitors and their patented scaffolds or specific compounds would need to be identified through comprehensive patent landscaping. This includes analyzing patents from companies active in oncology and kinase inhibitor development.
-
Marketed Drugs: Identifying currently marketed drugs that share structural similarities or target similar kinases could indicate potential infringement or prior art that might challenge the patent's validity. For instance, if a marketed drug uses an azaindole core for kinase inhibition, a detailed structural and claim analysis would be necessary.
-
Emerging Technologies: Newer patent filings and research may focus on overcoming limitations of older kinase inhibitor generations, such as improved selectivity, reduced off-target effects, or novel resistance mechanisms. This patent represents an earlier generation of small molecule kinase inhibitor technology.
Key Takeaways
US Patent 6,987,103 covers a broad class of azaindole derivatives designed as kinase inhibitors, primarily for treating proliferative disorders, including various cancers. The patent's claims define a specific chemical structure, Formula I, with broad variations in substituents. While the patent's original term extends to 2026, potential adjustments could alter this expiration date. The prior art landscape at the time of filing was characterized by significant activity in small molecule kinase inhibitor development. Enforcement and litigation considerations depend on precise claim interpretation and structural comparison with competitor products. The competitive landscape for azaindole kinase inhibitors is crowded, with multiple entities exploring this chemical space.
FAQs
-
Can any azaindole derivative be considered infringing under this patent?
No, infringement requires that a compound precisely matches the structural limitations defined by the patent's claims, including specific substituents and their allowed variations as per Formula I and dependent claims. Literal infringement occurs when a product falls within the scope of a claim.
-
What is the primary mechanism of action described for the compounds in US Patent 6,987,103?
The primary mechanism of action is the inhibition of protein kinases, which are enzymes involved in cell signaling pathways that regulate cell growth, proliferation, and survival.
-
Does this patent claim a specific drug?
This patent claims a genus of chemical compounds, represented by Formula I, rather than a single, specific drug. However, any drug developed by Novartis or other entities that falls within the scope of Formula I and is used for the claimed therapeutic indications would be covered by this patent.
-
What are the key challenges in enforcing this patent?
Key challenges include claim construction disputes, demonstrating infringement (especially under the doctrine of equivalents), and defending the patent's validity against challenges based on prior art or other patentability requirements.
-
How does the patent term of US 6,987,103 compare to regulatory exclusivities for a potential drug?
Patent term (20 years from filing, subject to PTA) runs concurrently with potential regulatory exclusivities (e.g., 5 years for NCEs from the FDA). If a drug based on this patent were approved, its market exclusivity would be determined by the FDA, and the patent term would still apply, providing protection for a defined period.
Citations
[1] Novartis AG. (2006). Azaindole derivatives and their use as kinase inhibitors (U.S. Patent No. 6,987,103). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
